The 21st Century Cures Act: Allowing The FDA To Address Modern Value Communication Needs
How to prove the real – and implicit – economic value of pharma products to payers and other stakeholders while FDA regulatory approvals adhere to a historically rigid standard of proof based on randomized tests against placebo in a controlled patient population? The 21st Century Cures Act may finally be extending a new path forward that offers legislative endorsement for use of a greater variety of evidence. What the FDA decides to do on this score is emerging as a key issue for biopharma in 2017.
Register for our free email digests: